Although, radiotherapy is an alternative therapeutic choice for patients with CRPC (3), the relapse presented following radiation therapy in 30–50% patients still (4, 5).One new and very effective strategy involves the administration of radio-ligands that target prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells. Here, FOLH1 is linked to prostate carcinoma.